Adoptive T cell therapy: An overview of obstacles and opportunities

Erez Nissim Baruch, Amy Lauren Berg, Michal Judith Besser, Jacob Schachter, Gal Markel*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

77 Scopus citations


The therapeutic potential of adoptive cell therapy (ACT) in cancer patients was first acknowledged 3 decades ago, but it was an esoteric approach at the time. In recent years, technological advancements have transformed ACT into a viable therapeutic option that can be curative in some patients. In fact, current ACT response rates are 80% to 90% for hematological malignancies and 30% for metastatic melanoma refractory to multiple lines of therapy. Although these results are encouraging, there is still much to be done to fulfill ACT's potential, specifically with regard to improving clinical efficacy, expanding clinical indications, reducing toxicity, and increasing production and cost-effectiveness. This review addresses the current major obstacles to ACT and presents potential solutions. Cancer 2017;123:2154-62.

Original languageEnglish
Pages (from-to)2154-2162
Number of pages9
StatePublished - 1 Jun 2017


  • T cell receptor
  • adoptive cellular immunotherapy
  • chimeric antigen receptor
  • immunotherapy
  • melanoma
  • tumor-infiltrating lymphocytes


Dive into the research topics of 'Adoptive T cell therapy: An overview of obstacles and opportunities'. Together they form a unique fingerprint.

Cite this